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SUMMARY
In 1996 an outbreak of severe soft tissue infections caused by Vibrio vulniﬁcus unexpectedly
erupted in ﬁsh consumers in Israel with relatively little morbidity in ﬁsh farmers. To test the
hypothesis that recurrent exposure of ﬁshermen to the virulent strain may have provided
protection against severe or symptomatic disease, we investigated the association between the
immune response to V. vulniﬁcus biotype 3 lipopolysaccharide (BT3 LPS) and disease
susceptibility in ﬁsh farmers and ﬁsh consumers. Serum samples were tested for IgA and IgG of
anti-BT3 LPS in ﬁshermen and ﬁsh consumers who suﬀered from V. vulniﬁcus BT3 infections and
their matched controls. Pre-existing levels of IgG (IgG0) of anti-BT3 LPS were signiﬁcantly lower
in diseased ﬁshermen who developed disease associated with the homologous biotype, compared
to controls. In multivariate analysis, levels of IgG0 anti-BT3 LPS remained the only variable
signiﬁcantly associated with disease occurrence in ﬁshermen. Higher levels of pre-existing IgG
anti-BT 3 LPS antibodies may be associated with protection against severe or symptomatic
disease with the homologous biotype in ﬁshermen but not in subjects from the general public.
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INTRODUCTION
Vibrio vulniﬁcus is the leading cause of seafood-
related death in the USA [1, 2]. The bacterium causes
three well described clinical syndromes, primary septi-
caemia, wound infections, and gastroenteritis. Severe
systemic infections are associated with high mortality
rates especially in immunocompromised hosts [3, 4].
In Israel, all disease cases have been characterized
by wound infections with or without bloodstream
infections [5, 6]. Currently, disease cases in Israel are
mostly conﬁned to ﬁshermen and ﬁsh-market workers
(N. Bisharat unpublished data). The causative or-
ganism of the disease outbreak in Israel was a new
strain of V. vulniﬁcus, named biotype 3 (BT3), which
was eventually implicated in all the conﬁrmed infec-
tions to date [5, 7]. The implicated ﬁsh was St Peter’s
ﬁsh (Tilapia zillii), the main type of ﬁsh cultivated
in inland ﬁsh farms in Israel. Analysis of the lipo-
polysaccharide (LPS) and outer membrane proteins
(OMPs) showed that V. vulniﬁcus BT3 expresses a
homogeneous LPS and exhibits highly conserved
nucleotide sequences in OMP-encoding genes [8].
To date, the only factor that has been clearly as-
sociated with virulence of V. vulniﬁcus is the capsular
polysaccharide (CPS) [9]. Many other factors have
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been suggested as playing an important role in the
pathogenesis of V. vulniﬁcus disease (LPS, acquisition
of iron, cytolysin, haemolysin, metalloprotease, RtxA
toxin, and pili) [9, 10]. LPS has been suggested by
some authors as one of the most essential factors
(as for most Gram-negative bacteria) for the devel-
opment of severe V. vulniﬁcus infections such as
severe soft tissue damage and septic shock [2, 10].
Animal studies showed that injecting puriﬁed LPS to
rats resulted in shock and death within 1 h [11] and
reversal of its action resulted in complete inhibition
of the toxic eﬀects [12]. While BT1 strains have vari-
able LPS O-polysaccharide side-chains, BT2 serovar
E and BT3 have a homogeneous LPS [8, 13]. To date
no deﬁnitive role has been established for the LPS
of BT1 strains; however, the O antigen side-chain of
BT2 serovar E strains does appear to be an important
virulence factor for eels [14]. Nevertheless, and despite
the clear association of V. vulniﬁcus LPS with the
classical endotoxic shock syndrome and its role in
determining virulence (at least in eels infected with
BT2), its role in eliciting an immune response is
questionable. Hitherto, analysis of the immune re-
sponse to LPS has been carried out only in eels
infected with BT2, and showed that the immuno-
protective potential of LPS was largely insigniﬁcant
[15–17]. The immune response to V. vulniﬁcus LPS in
humans has not been evaluated so far.
Analysis of the disease outbreak in Israel showed
that disease severity was variable, being generally
milder in ﬁshermen and ﬁsh-market workers com-
pared to diseased members of the general public
[N. Bisharat, unpublished data]. These diﬀerences in
disease manifestation may simply be attributed to the
health proﬁle of people working in the ﬁsh industry
(young and healthy males). In this regard, older age
and patients with pre-existing liver disease or compro-
mised immune systems are at particularly high risk for
severe outcome and fatal septicaemia [18–21]. Never-
theless, and given the frequent exposure to ﬁsh and
ﬁsh-farm water it is possible that occupational ex-
posure in ﬁshermen and ﬁsh-market workers may
have provided some protection against severe or symp-
tomatic infection.
We have utilized the unique epidemiology of the
disease in Israel, where all the conﬁrmed infections to
date were caused by a single biotype expressing a
homogeneous LPS, to study the human immune re-
sponse to V. vulniﬁcus LPS and test the association
between antibodies to LPS and disease susceptibility
in ﬁshermen and ﬁsh consumers.
METHODS
Study groups, study design and data collection
Study groups
The study groups included members of the general
public and ﬁshermen who suﬀered from laboratory-
conﬁrmed V. vulniﬁcus infection and their matched
controls. Serum samples were obtained from all par-
ticipants. The local ethics committee at Ha’Emek
Medical Center approved the study and informed
consent was obtained from all participants. Over a
2-year period four groups of participants were re-
cruited. The ﬁrst group consisted of patients (n=20)
from the general public who suﬀered from soft tissue
infection (with or without bacteraemia) after handling
pond-cultivated ﬁsh, where V. vulniﬁcus was grown
from blood or wound cultures. The second group
consisted of controls (from the general public)
matched by age, sex and comorbidities as for the ﬁrst
group, but who had never handled pond-cultivated
ﬁsh or suﬀered from any ﬁsh-related disease (n=40).
The third group consisted of ﬁshermen and ﬁsh-
market workers who suﬀered from laboratory-
conﬁrmed V. vulniﬁcus infection (n=10). The fourth
group consisted of healthy ﬁshermen and ﬁsh-market
workers (n=40) with the same risk of exposure to
V. vulniﬁcus as the infected ﬁshermen. Disease severity
was assessed based on the extent of the soft tissue
damage and the need for surgical intervention.
Study design
Diﬀerent approaches in designing the study were used
to address the study objectives ; a prospective study
and a case-control study. The sensitivity, speciﬁcity,
dynamics and persistence of the serological response
to V. vulniﬁcus BT3 LPS was examined in frame of
a prospective study. The sensitivity and speciﬁcity of
the ELISA test was determined using paired sera
(acute and convalescent samples) from subjects with
laboratory-conﬁrmed infection caused by V. vulniﬁcus
BT3. The rate of signiﬁcant antibody response to the
homologous and heterologous V. vulniﬁcus BT3 LPS
in these subjects was compared to that measured
in sera obtained from subjects with no known pre-
vious exposure to V. vulniﬁcus. To study the dynamics
and long-term persistence of serum IgG and IgA
antibodies to V. vulniﬁcus BT3 LPS, a cohort of new
cases infected withV. vulniﬁcus BT3 was recruited and
followed up while blood samples were obtained at the
acute stage of the disease, 4–6 weeks later, at 6months,
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and at 1 year. A curve of IgG and IgA antibody levels
to V. vulniﬁcus BT3 LPS by the various time inter-
vals from the laboratory-documented infection was
drawn.
Case-control studies
Two case-control studies were conducted to examine
the role played by ‘pre-existent’ (acute stage) V. vul-
niﬁcus LPS antibodies and the risk of developing
symptomatic infection and severe disease. In one
study, cases were ﬁshermen who developed infection
with V. vulniﬁcus BT3 (n=10) while controls (n=40)
were ﬁshermen who had similar risk (working in the
same ﬁsh pond with similar exposure potential to ﬁsh
or ﬁsh-pond water) of exposure to cases but did not
develop symptomatic infection. The level of serum
IgG and IgA antibodies to V. vulniﬁcus BT3 LPS was
measured in cases and controls immediately after the
onset of disease in cases. A paired serum sample
was obtained from cases and controls during con-
valescence (4–6 weeks), at 6 months and at 1 year. In a
second case-control study, cases were patients from
the general public who suﬀered from laboratory-
conﬁrmed V. vulniﬁcus BT3 infection (n=20) after
handling pond-cultivated ﬁsh. Controls (n=40) were
volunteers recruited at primary health clinics in the
Ha’Amakim district matched by age, sex and co-
morbidities to cases but who had never handled pond-
cultivated ﬁsh or suﬀered from any ﬁsh-related
disease. Serum samples were obtained during the
acute phase, at 6 weeks, at 6 months, and at 1 year.
Questionnaires were used to obtain data from cases
and controls. For cases the data included age, sex,
occupation, pre-existing comorbidities, time from
exposure to disease onset, site of infection, type of
antimicrobial therapy, type of surgical intervention,
outcome and residual function of the infected site.
For controls the data included age, sex, speciﬁc oc-
cupation and duration of work at ﬁsh ponds, pre-
existing comorbidities, type of exposure to ﬁsh-pond
cultivated ﬁsh (ﬁsh cultivation, ﬁsh processing, ﬁsh
marketing), history of admission due to a ﬁsh-
associated illness, and outcome. The local ethics
committee at Ha’Emek Medical Center approved the
study and informed consent was obtained from all
participants.
LPS extraction and ELISA
Crude LPS was extracted from whole cells of selected
strains of all three biotypes, ATCC 27562 BT1, CECT
4604 BT2 serovar E, and ATCC BAA-86 BT3. LPS
was extracted using the LPS Extraction kit (Intron
Biotechnology, Korea) according to the manufac-
turer’s instructions and using basically the water–
phenol method of Westphal & Jann [22]. Speciﬁc
serum IgG and IgA antibodies to the homologous
(LPS BT3) and heterologous (BT1 and BT2) V. vul-
niﬁcus were measured in patients and controls by
means of ELISA in double dilutions starting with
1:100 dilution for IgG and 1:50 for IgA. Brieﬂy,
100 ml of a solution containing 5 mg LPS/1 ml, a
coating buﬀer (0.05 M carbonate buﬀer; pH 9.6) was
added to each of 96 wells in a microtitration plate
(Coaster, Corning, USA), and incubated for 1 h at
37 xC. After removal of the coating solution, the
plates were incubated for 1 h at 37 xC with 0.05 M
phosphate-buﬀered saline (PBS) test buﬀer supple-
mented with casein and bovine serum albumin in
order to block the remaining unbound plastic sites.
The wells were then washed twice in PBS-0.05%
Tween-20 washing solution (Dulbecco’s PBS, Bio-
logical Industries, Israel). Sera were added to the wells
in twofold dilutions in PBS test buﬀer and then in-
cubated overnight at room temperature. After four
further washings with PBS-0.05% Tween-20 washing
solution, goat anti-human anti-anti-IgG, or anti-IgA,
conjugated to alkaline phosphatase (Kirkegaard &
Perry Laboratories, USA) and diluted 1:1500 with
PBS test buﬀer was added to the wells and incubated
overnight at room temperature. ELISA was com-
pleted sequentially by the addition of the enzyme
substrate solution containing para-nitrophenylpho-
sphate (1 mg/ml) in diethanolamine buﬀer at pH 9.8
and 3 M NaOH. Optical density (OD) was read at
405 nm with an automatic ELISA reader (Multiskan
EX, Thermo Scientiﬁc, USA). Positive and negative
control sera were included in every microtitration
plate in each of the assays. IgG and IgA antibody
levels were expressed in ELISA units calculated by
multiplying the ODs with the dilution factor and
dividing the product by the number of the dilutions
tested. Antibody titres were expressed as geometric
mean titres (GMTs) using logarithmic-transformed
data of the ELISA titres (a geometric mean is calcu-
lated by averaging the logarithms of the test values
and then converting the mean to a number, this
prevents high values from making the mean unreal-
istically large). The inter-V. vulniﬁcus biotype speci-
ﬁcity of the antibody response was documented by
absorption assays in which sera (from three diﬀerent
patients infected with V. vulniﬁcus BT3) with high
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titres of antibodies to V. vulniﬁcus BT3 were pre-
incubated with the homologous- and heterologous-
soluble LPS before being tested against V. vulniﬁcus
BT3 LPS. A concentration of 50 mg/ml of V. vulniﬁcus
BT3 LPS was used as soluble antigen for the absorp-
tion studies.
To determine an accurate cut-oﬀ value which will
document a signiﬁcant increase in ELISA antibody
titres to V. vulniﬁcus BT3 LPS, we used 23 pairs of
archived sera obtained in another study from healthy
volunteers with no risk of exposure to V. vulniﬁcus at
two consecutive time periods (0 and 6 weeks). These
sera were tested for anti-BT3 LPS antibodies. The
mean ratio (of titres at time 0 and 6 weeks later) was
0.98¡0.46 S.D. In a normal distribution 95% of
samples will fall between ¡2 S.D. (actually ¡1.96
S.D.), when adding 2 S.D., the upper value of the mean
ratio rose to 1.9. This was the cut-oﬀ value which was
used throughout the study to detect signiﬁcant anti-
body response to V. vulniﬁcus LPS.
Statistical analysis
The data management and statistical analyses were
performed using SPSS software (SPSS Inc., USA).
GMTs and 95% conﬁdence intervals were determined
using logarithmic-transformed data. GMTs of IgG
and IgA antibodies to V. vulniﬁcus LPS in the various
study groups and at the various times following ex-
posure were compared by Student’s t test or ANOVA.
Variables such as age, years of occupational exposure,
or pre-existing comorbidities constituted potential
confounding factors of the possible association be-
tween serum antibody levels and the risk of develop-
ing symptomatic infection and severe infection with
the pathogen. The eﬀect of these variables handled as
independent variables on the risk of developingV. vul-
niﬁcus infection and their possible interaction with
the level of LPS speciﬁc serum antibodies was as-
sessed by univariate and multivariate analyses. As a
criterion for inclusion of variables in the multivariate
and logistic regression analysis, only variables with
a P value f0.05 obtained in the bivariate analysis
were allowed for assessment of potential confound-
ing. Signiﬁcance was determined at the 0.05 level.
RESULTS AND DISCUSSION
Study group characteristics
During 3 years of subject enrolment and data collec-
tion, 20 patients from the general public and 10 ﬁsh-
ermen patients with laboratory-conﬁrmedV. vulniﬁcus
BT3 infection were recruited to the study. For the
ﬁrst group of patients from the general public 40 con-
trols were matched by age, sex, and other comor-
bidities. For the second group of patients (ﬁshermen),
40 healthy ﬁshermen served as controls. The clinical
characteristics of the two groups of patients and their
controls are shown in Table 1.
The groups enrolled in the study were studied in
two patterns, the ﬁrst, a prospective study where we
Table 1. Characteristics of the study groups
General public
Fishermen and
ﬁsh-market workers
Patients Controls Patients Controls
Number of subjects 20 40 10 40
Mean age (yr) 57.4 60.7 26.3 32.1
Sex (% male) 53% 54% 100% 100%
Mean length of
hospital stay (days)
7.3 n.a. 4.2 n.a.
Liver disease (%) 2 (10%) 6 (15%) 0 0
Diabetes mellitus 7 (35%) 15 (38%) 0 0
Malignancy 1 (5%) 3 (7.5%) 0 0
Bloodstream infection 9 (45%) n.a. 3 (30%) n.a.
Surgical intervention 12 (60%) n.a. 2 (20%) n.a.
Mean years of
occupational exposure
n.a. n.a. 5.5 11.8
Death 0 n.a. 0 n.a.
n.a., Not applicable.
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examined the sensitivity, speciﬁcity, and dynamics of
the serological response to the LPS of V. vulniﬁcus
BT3 in patients and controls. The second, a case-
control study was conducted to test the role of
antibodies to V. vulniﬁcus BT3 LPS in disease sus-
ceptibility in ﬁsh farmers and ﬁsh consumers.
Sensitivity and speciﬁcity of serum antibody response
We found that 60% of diseased ﬁshermen and up to
78% of diseased members of the general public had
a signiﬁcant antibody rise to V. vulniﬁcus BT3 LPS
(determined as 1.9-fold rise in titre ratio between IgG
and IgG0 at any of the follow-up points). However,
in diseased members of the general public admitted
with severe disease (severe soft tissue infection with
or without bloodstream infection) about 90% had a
signiﬁcant antibody rise.
To document the speciﬁcity of the antibody
response to V. vulniﬁcus LPS we performed absorp-
tion assays (Fig. 1). The assays were performed in
several steps, initially, and to evaluate the impact of
assay background levels, we used sera from three
uninfected individuals and incubated with BT3 LPS
(Fig. 1, B). Next, we used sera of three patients with
laboratory-conﬁrmedV. vulniﬁcusBT3 disease and in-
cubated with the homologous-soluble LPS (Fig. 1, C)
and in parallel with the LPS of BT1 (Fig. 1, D), LPS
of BT2 (Fig. 1, E), and then again with the LPS of
BT3 (Fig. 1, F). The mixture of serum from patients
infected with BT3 (initially absorbed with BT3 LPS)
with LPS from BT1 or BT2 did not aﬀect the ELISA
reactivity ; however, further absorption of the sera
with the homologous LPS (BT3) was associated with
a signiﬁcant reduction in the ELISA reactivity. These
results indicated that the antibody response to LPS
of V. vulniﬁcus BT3 was speciﬁc and was not aﬀected
by exposure to the heterologous biotypes.
Dynamics of serum antibody response to V. vulniﬁcus
BT3 LPS
The dynamics of the antibody response (IgG and IgA)
to the LPS of BT3 in patients from the general public,
infected ﬁshermen, and healthy close-control ﬁsher-
men are shown in Figure 2. The GMTs of IgG and
IgA from patients (general public and ﬁshermen)
showed a statistically signiﬁcant rise between disease
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Fig. 1.Absorption assays. Biotype 3 lipopolysaccharide (BT3 LPS) served as an antigen in all the ELISA reactions. A, blank;
B, sera of three uninfected healthy controls ; C–F, sera of three patients infected with BT3 were pre-incubated with LPS of
BT3. Initially no other LPS was added (C), then incubated in parallel with LPS of BT1 (D), with LPS of BT2 (E), and then
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onset and convalescence (P=0.016 and P=0.03,
respectively). Subsequently GMTs decreased at
6 months but were still signiﬁcantly higher than the
disease acute stage levels. Yet, in healthy ﬁshermen
controls no signiﬁcant changes were observed in
antibody titres over time (P=0.67).
Occupational exposure and anti-LPS antibodies
The average number of years of occupational ex-
posure for infected ﬁshermen was 5.5 years, compared
with 11.8 years for healthy controls (P<0.01). The
GMTs of IgG0 and IgA0 (IgG and IgA levels at dis-
ease onset for infected ﬁshermen and at the same time
frame for controls) are shown in Table 2. Fishermen
who developed V. vulniﬁcus BT3-associated diseases
had signiﬁcantly lower levels of IgG0 (but not IgA0) to
BT3 LPS than controls. In multivariate analysis
including age, years of exposure, levels of IgG0 and
IgA0, pre-existing antibodies to V. vulniﬁcus (IgG0)
anti-LPS BT3 was the only variable found to be
signiﬁcantly associated with disease occurrence in
ﬁshermen.
To assess the natural exposure to the three V. vul-
niﬁcus biotypes, the sera of 10 ﬁshermen infected
with V. vulniﬁcus BT3 and 20 matched controls were
tested for signiﬁcant antibody response to LPS of BT1
and BT2 during the year of follow-up (Table 3). The
experiments, including the establishment of control
ranges, were performed in a similar fashion to that
described for BT3 in the Methods section (see ‘LPS
extraction and ELISA’). Table 3 shows for every
individual the presence or lack of signiﬁcant antibody
rise to the LPS of each of the three biotypes [shown
as pluses and minuses, a plus indicates a signiﬁcant
(at least 1.9-fold rise) antibody rise and a minus is a
ratio that is<1.9]. Nearly 25% of healthy ﬁshermen
were found to have a signiﬁcant rise in anti-BT1 LPS
during the year of follow-up (Table 3). One of the
ﬁshermen infected with V. vulniﬁcus BT3 also showed
a signiﬁcant serum antibody response to V. vulniﬁcus
BT1 LPS. No signiﬁcant antibody rises for BT2 LPS
were detected in patients or controls.
Pre-existing anti-LPS antibodies in patients and
controls from the general public
There were no statistically signiﬁcant diﬀerences
in levels of pre-existing antibodies to LPS of BT3 in
patients from the general public and their controls,
GMTs for IgG to BT3 LPS from patients were 153.2
and from controls 122.1 (P=0.18). Interestingly,
levels of pre-existing LPS antibodies in patients from
the general public were signiﬁcantly higher than those
measured in infected ﬁshermen (IgG0 : 153.2 vs. 88.9) ;
however, when controlling for age these diﬀerences
disappeared (Table 4).
The emergence of V. vulniﬁcus disease in Israel was
regarded as an epidemiological mystery. Since its ﬁrst
description in 1996 [23], several studies had elab-
orated the nature and causes of this outbreak. At the
species level a genetically distinct [7] and highly clonal
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Fig. 2. Dynamics of (a) IgG and (b) IgA antibodies to bio-
type 3 lipopolysaccharide (BT3 LPS) in patients from the
general public (–&–), infected ﬁshermen (–#–), and healthy
ﬁshermen controls ( ). GMT, Geometric mean titre.
Table 2. Levels of pre-existent antibodies to
lipopolysaccharide of V. vulniﬁcus biotype 3 in
ﬁshermen
Group
No. of
subjects IgG0¡S.D. IgA0¡S.D.
Patients 10 88.9¡15.2 18.8¡8.2
Controls 40 147.4¡11.8 20.2¡7.3
P value 0.034 0.7
IgG0, IgG at disease onset ; IgA0, IgA at disease onset ; S.D.,
standard deviation.
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biotype was found to be the causative organism [8].
Human behaviour [23] and global warming [24] may
have impacted upon the timing of the disease out-
break. The current study investigated the association
between the immune response to V. vulniﬁcus BT3
LPS and disease susceptibility in Israeli ﬁsh farmers
and ﬁsh consumers.
The antibody response to V. vulniﬁcus BT3 LPS
was shown to be speciﬁc. We found that 60% of dis-
eased ﬁshermen and up to 78% of diseased members
of the general public had a signiﬁcant antibody re-
sponse to V. vulniﬁcus BT3 LPS. Furthermore, nearly
90% of patients with severe disease had a signiﬁcant
increase in anti-LPS antibodies. This suggests that
Table 3. IgG antibody titres between convalescence and disease onset* to
lipopolysaccharide of three V. vulniﬁcus biotypes in ﬁshermen infected with
biotype 3 (BT3) and their matched controls
Individual
tested
Fishermen infected with
BT3 (n=10)
Healthy ﬁshermen controls
(n=20)
BT1 BT2 BT3 BT1 BT2 BT3
1 x x + x x x
2 x x x x x x
3 x x + + x x
4 x x x x x x
5 + x + x x +
6 x x + x x x
7 x x x x x x
8 x x x + x x
9 x x + + x x
10 x x + x x x
11 n.a. n.a. n.a. x x x
12 n.a. n.a. n.a. x x x
13 n.a. n.a. n.a. x x x
14 n.a. n.a. n.a. x x x
15 n.a. n.a. n.a. + x x
16 n.a. n.a. n.a. x x x
17 n.a. n.a. n.a. x x x
18 n.a. n.a. n.a. + x x
19 n.a. n.a. n.a. x x x
20 n.a. n.a. n.a. x x x
n.a., Not applicable.
The data are shown as pluses and minuses, a plus indicates a signiﬁcant (o1.9-fold
rise) antibody rise and a minus is a ratio that is<1.9.
* For patients only, for controls the highest ratio within a year of follow-up
was used.
Table 4. Pre-existing antibodies to lipopolysaccharide of V. vulniﬁcus
bioptype 3 in patients and controls from the general public
Agef65 yr Age>65 yr
Patients Controls Patients Controls
No. 8 17 12 23
IgG0 115.6
(52–256.8)
120.5
(91.1–159.5)
202.9
(122.6–335.8)
124.2
(71.1–216.8)
P value n.s. n.s.
n.s., Not signiﬁcant.
Values are geometric mean titres of anti-lipopolysaccharide antibodies (95% CI).
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V. vulniﬁcus LPS is immunogenic and elicits an im-
mune response in most severely infected patients.
Nearly 25% of healthy ﬁshermen controls had a sig-
niﬁcant rise in antibody titres to BT1 LPS. This can
reﬂect more or continuous exposure to BT1 compared
to the lack of exposure to BT2 as suggested by eco-
logical studies in Israel (N. Bisharat, unpublished
data). Nevertheless, and given the fact that the LPS
of BT1 strains are not homogenous, it is entirely
possible that ﬁshermen could have been exposed to
BT1 strains that had diﬀerent LPS types than those
used for the absorption studies, clearly underestimat-
ing the true exposure rates to these two biotypes.
Two case-control studies were conducted in order
to test the role played by pre-existing antibodies to
V. vulniﬁcus BT3 LPS in disease susceptibility in
ﬁshermen and members of the general public. The
ﬁrst study which included 10 ﬁshermen patients and
40 healthy matched controls showed that ﬁshermen
patients had worked less time in ﬁsh farming and had
signiﬁcantly lower levels of IgG0 to V. vulniﬁcus BT3
LPS than controls. This could imply that continuous
or recurrent exposure to V. vulniﬁcus BT3 may
have conferred some protection to controls against
symptomatic infection. In multivariate analysis, pre-
existing levels of IgG anti-LPS BT3 remained the only
variable signiﬁcantly associated with disease occur-
rence. In the second case-control study which in-
cluded 20 patients from the general public (ﬁsh
consumers) and 40 matched controls, and after con-
trolling for age, there was no diﬀerence in pre-existing
levels of IgG between patients and controls. These
interesting observations could suggest that, unlike
ﬁshermen, the role of pre-existing anti-LPS antibodies
in conferring protection from symptomatic disease
might be overwhelmed by other factors such as old
age and other comorbidities which are more inﬂuen-
tial in determining disease susceptibility [10, 20, 25].
Nevertheless, the correlation between old age and
levels of anti-LPS antibodies is intriguing. Several
previous studies have demonstrated the increasing
prevalence of antibodies with advancing age [26–28],
probably mirroring the increasing comorbidity and
disability with advancing age. It is possible that high
levels of anti-LPS antibodies in this subgroup are due
to age-related non-speciﬁc antibodies cross-reacting
with the LPS antigen. In fact, a previous work that
tested the prevalence of antibodies against CPS of
V. vulniﬁcus in patients with conﬁrmed V. vulniﬁcus
BT1 infections, shellﬁsh industry workers, and in un-
infected persons with minimal occupational exposure,
found that antibodies were demonstrable in persons
without a previous history of V. vulniﬁcus infection or
occupational exposure [29]. The authors concluded
that cross-reacting antibodies to CPS are present
in the general population. It may be possible that
older age provides a wider window of opportunity to
develop such cross-reacting antibodies.
IgA levels in healthy and diseased ﬁshermen
throughout the follow-up period were signiﬁcantly
lower than IgG levels ; furthermore, pre-existing IgA
anti-BT3 LPS antibodies were not associated with
protection against severe or symptomatic disease in
ﬁshermen. These observations are consistent with
current knowledge concerning the limited immuno-
protective role of IgA in host defence against non-
mucosal and non-enteric bacterial infections [30].
The single work that tested the immunogenic pro-
ﬁle of LPS of V. vulniﬁcus was carried out in eels. The
use of LPS-based vaccines against vibriosis in eels
was not promising and the authors suggested that
LPS from V. vulniﬁcus serovar E may not be immuno-
genic for eels [16]. Conjugation of V. vulniﬁcus LPS to
carrier proteins might be helpful in increasing the
immunogenicity of potential vaccines in eels. The
same approach can be considered for development of
V. vulniﬁcus candidate vaccines in humans, especially
in elderly people where the speciﬁc immune response
after natural exposure might be insuﬃcient to provide
future protection. This approach has been evaluated
for some of the most important human pathogenic
Gram-negative bacteria, such as Vibrio cholerae [31],
Shigella sonnei [32], Escherichia coli O157 [33], and
recently for Neisseria meningitides [34].
Our study has a few limitations. First, the number
of ﬁshermen patients with laboratory-conﬁrmed in-
fection was small, many ﬁshermen who suﬀered from
soft tissue infection after handling pond-cultivated
ﬁsh but had negative cultures were considered highly
probable cases but were excluded from the study.
Given the limited number of populations from which
to draw subjects, this has aﬀected the number of
patients recruited for the study. Second, we included
only survivors from the general public. To date, no
deaths have been reported in ﬁshermen infected
with V. vulniﬁcus in Israel (N. Bisharat, unpublished
data). V. vulniﬁcus mortality rates in Israel are fortu-
nately much lower than ﬁgures reported from the
USA or Southeast Asia (y8% vs. 25–53%) [6, 20,
35, 36], this discrepancy is mainly attributed to food
habits, eating raw or undercooked seafood which
is the main source of infection in the USA and
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Southeast Asia, is extremely uncommon in Israel, thus
limiting disease burden and its related mortality.
Third, given the possible similarities in some antigenic
determinants in the LPS of the three biotypes we
cannot rule out some cross-reactivity in anti-LPS
antibodies. Nonetheless, and given the homogeneous
properties of BT3 LPS and the results of the absorp-
tion assays we considered these eﬀects as marginal.
In summary, the data showed that the antibody
response to V. vulniﬁcus BT3 LPS is speciﬁc. It also
showed that higher levels of pre-existing IgG anti-
BT3 LPS antibodies might have protected ﬁshermen
and ﬁsh-market workers against symptomatic infec-
tion but not in members of the general public.
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